Erratum: Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation (Journal of Oncology Pharmacy Practice (2008) vol. 14(3) 10.1177/1078155208089846);Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation

Journal of Oncology Pharmacy Practice

Volumn 14, Issue 3, 2008, Pages 113-121

  Ibrahim, Rami B ^a,f   Abidi, Muneer H ^a,b   Ayash, Lois J ^a,b   Cronin, Simon M ^c   Cadotte, Cheryl ^d   Mulawa, Jason ^c   Jacobson, Pamela A ^e   Smith, Daryn W ^a   Uberti, Joseph P ^b   Edwards, David J ^c  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d HARPER UNIVERSITY HOSPITAL   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f Department of Pharmacy   (United States)

Author keywords

Aprepitant; Cytochrome CYP3A4; Inhibition; Interaction; Tacrolimus

Indexed keywords

ACICLOVIR; APREPITANT; BUSULFAN; DIPHENHYDRAMINE; FLUCONAZOLE; FLUDARABINE; GRANISETRON; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORFLOXACIN; PHENYTOIN; PROCHLORPERAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; URSODEOXYCHOLIC ACID; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; MORPHOLINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DISPOSITION; DRUG METABOLISM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; LIVER DYSFUNCTION; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; ADOLESCENT; DOSE RESPONSE; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION TEST; MIDDLE AGED; MYCOSIS;

ADOLESCENT; ADULT; ANTIEMETICS; ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MORPHOLINES; MYCOSES; RETROSPECTIVE STUDIES; TACROLIMUS; YOUNG ADULT;

EID: 58249085931     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155208098835     Document Type: Erratum

References (40)

1. Dando TM, Perry CM Aprepitant: A review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004; 64: 777-94.
2. Massaro AM, Lenz KL Aprepitant: A novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother 2005; 39: 77-85.
3. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F., de Wit R. et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-9.
4. Warr DG, Grunberg SM, Gralla RJ, Warr DG, Roila F., de Wit R. et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005; 41: 1278-85.
5. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J., Eisenberg PD et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea andvomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23: 2822-30.
6. Kris MG, Hesketh PJ, Somerfield MR, Feyer P., Clark-Snow R., Koeller JM et al. American Society of Clinical Oncologyguideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006; 24: 2932-47.
7. Shadle CR, Lee Y., Majumdar AK, Petty KJ, Gargano C., Bradstreet TE et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004; 44(3): 215-23.
8. Sanchez RI, Wang RW, Newton DJ, Bakhtiar R., Lu P., Chiu SH et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004; 32: 1287-92.
9. Majumdar AK, McCrea JB, Panebianco DL, Hesney M., Dru J., Constanzer M. et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003; 74: 150-6.
10. McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M., Gargano C., Panebianco DL et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003; 74: 17-24.
11. de Jonge ME, Huitema AD, Holtkamp MJ, van Dam SM, Beijnen JH, Rodenhuis S. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005; 56: 370-8.
12. Leather H., Boyette RM, Tian L., Wingard JR et al. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimusor intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006; 12: 325-34.
13. Leather HL Drug interactions in the hematopoietic stemcell transplant recipient: What every transplanter needs to know. Bone Marrow Transplant 2004; 33: 137-52.
14. Mignat C. Clinically significant drug interactions withnew immunosuppressive agents. Drug Saf 1997; 16: 267-78.
15. Przepiorka D., Devine S., Fay J., Uberti J., Wingard J. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. Bone Marrow Transplant 1999; 24: 1053-6.
16. Przepiorka D., Nash RA, Wingard JR, Zhu J., Maher RM, Fitzsimmons WE et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant 1999; 5: 94-7.
17. Jacobson P., Ng J., Ratanatharathorn V., Uberti J., Brundage RC Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant 2001; 28: 753-8.
18. Ibrahim RB, Abella EM, Chandrasekar PH Tacrolimusclarithromycin interaction in a patient receiving bone marrow transplantation. Ann Pharmacother 2002; 36(12): 1971-2.
19. Said A., Garnick JJ, Dieterle N., Peres E., Abidi MH, Ibrahim RB Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 2006; 26(2): 289-95.
20. Marr KA, Leisenring W., Crippa F., Slattery JT, Corey L., Boeckh M. et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-9.
21. Cagnoni PJ, Matthes S., Day TC, Bearman SI, Shpall EJ, Jones RB Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999; 24: 1-4.
22. Gilbert CJ, Petros WP, Vredenburgh J., Hussein A., Ross M., Rubin P. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 1998; 42: 497-503.
23. Yule SM, Boddy AV, Cole M., Price L., Wyllie R., Tasso MJ et al. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 1996; 41: 13-19.
24. Jacobson P., Uberti J., Davis W., Ratanatharathorn V. Tacrolimus: A new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 22: 217-25.
25. Staatz CE, Tett SE Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623-53.
26. Merck and Co. Inc. Aprepitant (Emend) package insert. Whitehouse Station, NJ; June 2006.
27. Blum RA, Majumdar A., McCrea J., Busillo J., Orlowski LH, Panebianco D. et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003; 25(5): 1407-19.
28. Shah AK, Hunt TL, Gallagher SC, Cullen Jr, MT Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin 2005; 21: 595-601.
29. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C. Elmer ME Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 2290-300.
30. Poli-Bigelli S., Rodrigues-Pereira J., Carides AD, Julie Ma, Eldridge K., Hipple AS et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090-8.
31. Nygren P., Hande K., Petty KJ, Fedgchin M., van Dyck K., Majumdar A. et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005; 55: 609-16.
32. Loos WJ, Murphy GM, van Noort C., de Bruijn P., Verweij J. et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007; 59: 407-12.
33. Bubalo JS, Leis JF, Curtin PT, Kovascovics TJ, Meyers G., Hayes-Lattin B. et al. A double blinded pilot study of aprepitant vs placebo combined with standard antiemetics for the control of nausea and vomiting during hematopoietic cell transplantation. Biol Bone Marrow Transplant 2007; 13: 152 (Abstract 425).
34. Durand JP, Gourmel B., Mir O., Goldwasser F. Anti-emetic neurokinin-1 antagonist aprepitant and ifosfamideinduced encephalopathy. Ann Oncol 2007; 18: 808-09.
35. Howell J., Szabatura A., Nesbit S., Hatfield A. Characterization of the occurrence of the ifosfamideinduced neurotoxicity with concomitant aprepitant. J Oncol Pharm Pract 2007; 14(3): 157-62.
36. Mori T., Shimizu T., Yamazaki R., Nakazato T., Ikeda Y., Okamoto S. Altered metabolism of tacrolimus in hepatic veno-occlusive disease. Transpl Int 2005; 18: 1215-7.
37. Plosker GL, Foster RH Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59: 323-89.
38. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V., Gan L., Grimm S. et al. The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815-32.
39. Feuring M., Lee Y., Orlowski LH, Michiels N., De Smet M., Majumdar AK et al. Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. J Clin Pharmacol 2003; 43: 912-7.
40. Bjornsson TD, Wagner JA, Donahue SR, Harper D., Karim A., Khouri MS et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 2003; 43(9): 943-67.